ASX Health Stocks: BOD to sell cannabis in Malaysia; AHI explores Middle East e-script market
Biotech Bod Science has signed a milestone agreement with powerhouse Antah Group to identify, develop and commercialise medical cannabis in Malaysia.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Cannabis focused biotech Bod Science (ASX:BOD) has signed a milestone collaboration agreement with Malaysian powerhouse, Antah Group.
The Letter of Intent sets the framework between the two companies to identify, develop and commercialise medical cannabis products in Malaysia.
This marks the first opportunity to explore the use of cannabidiol (CBD) in the Malaysian healthcare industry.
For the latest health news, sign up here for free Stockhead daily newsletters
Under the deal, Bod and Antah will identify indications that are expected to benefit from medical cannabis therapy upon the establishment of a regulated medical cannabis market in Malaysia. These may include autism spectrum disorder, anxiety disorders and major depression.
To date, there have been no clinical trials or opportunity to explore the use of medical cannabis in the Malaysian healthcare industry, however Antah is positive they will be available in the near future.
When regulation is passed, Bod’s patented products are expected to provide the base for any randomised controlled trials.
On successful completion of the trials, Antah will have exclusive use of Bod’s investigational medical product for sales and distribution, which would provide the first-mover advantage in the Malaysian market.
MORE FROM STOCKHEAD: Vaxxas shows off needle-free vaccines | How Zelira took on Big Pharma | Big step for spray-on skin device
This announcement comes with news neighbouring Thailand’s legal cannabis market is expected to reach $US9.6 billion by 2030.
The adoption of medical cannabis in Thailand to treat various ailments such as nausea and anxiety are some of the significant factors boosting the industry’s growth in the country.
AHI to expand in the Middle East
Healthcare software company Advanced Health Intelligence (ASX:AHI) has also signed a LOI, with UAE-based e-script medicine management company, Pharmak Pharmacy.
Under the deal, Pharmak will integrate the AHI Biometric Health Assessment (BHA) software into its own system.
Once integrated, Pharmak will deliver AHI’s e-script and screening solution to all current and future Pharmak partners, which include health insurers, government, and healthcare professionals in the Middle East.
Visit Stockhead, where ASX small caps are big deals
Pharmak expects to achieve a minimum e-script order volume in 2024 of 100,000 e-scripts per month in the UAE, and a further 100,000 e-scripts per month in Saudi Arabia.
The average e-script value in the UAE is AED550 (around $US150). In Saudi, that value is SAR350.00 (USD$93.40).
The partnership comes at a time when the Middle East region is extremely vocal regarding its intention to invest heavily in the digitisation of healthcare and population screening
In Saudi Arabia alone, the Kingdom has allocated $US50.3 billion to healthcare and social development.
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here
Originally published as ASX Health Stocks: BOD to sell cannabis in Malaysia; AHI explores Middle East e-script market
Investor Guide: Health & Biotech FY2025
In this special investor guide, health and biotech guru Tim Boreham leads Stockhead’s deep dive into the most cutting edge sector on the ASX.
Investor Guide: Gold & Copper FY2025
Stockhead's writers - including mining guru Barry FitzGerald - take you inside the copper and gold markets, and zero in on juniors exploring for the next major mine.